الإحصائيات الأساسية
| LEI | 549300LCY1NZSXCQDT45 |
| CIK | 1388320 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Actinium Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM P |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| May 9, 2025 |
Letter from Marcum dated May 09, 2025 Exhibit 16.1 May 9, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Actinium Pharmaceuticals, Inc. under Item 4.01 of its Form 8-K dated May 9, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of INmune Bio Inc. contained the |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Actinium Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction (Commission File Number) |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 001-36374 ACTINIUM PHARM |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTIN |
|
| November 8, 2024 |
ATNM / Actinium Pharmaceuticals, Inc. / Bigger Capital, LLC Passive Investment SC 13G/A 1 sc13ga510022atnm11082024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| November 5, 2024 |
Exhibit 99.1 Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium’s Nominating and Corporate Governance Committee NEW YORK, NY – November 04, 2024 – Actinium Pharmaceutic |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM P |
|
| August 5, 2024 |
Exhibit 99.1 Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. - FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint - Additional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to support |
|
| August 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 29, 2024 |
Actinium Pharmaceuticals, Inc. Compensation Recovery Policy. Exhibit 97.1 ACTINIUM PHARMACEUTICALS, INC. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) of Actinium Pharmaceuticals, Inc. (the “Company”) is hereby adopted as of December 1, 2023, in compliance with Section 811 of the NYSE American Company Guide. Certain terms shall have the meanings set forth in “Section 3. Definitions” below. Section 1. Recovery Requirement Sub |
|
| March 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Actinium Pharmaceuticals, Inc. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 001-36374 ACTINIUM PHARM |
|
| February 9, 2024 |
ATNM / Actinium Pharmaceuticals, Inc. / Bigger Capital, LLC Passive Investment SC 13G/A 1 sc13ga410022atnm02092024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of |
|
| February 2, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| February 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Actinium Pharmaceuticals, Inc. |
|
| February 2, 2024 |
Actinium Pharmaceuticals, Inc. 100 Park Ave., 23rd Floor New York, NY 10017 Actinium Pharmaceuticals, Inc. 100 Park Ave., 23rd Floor New York, NY 10017 February 2, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Dillon Hagius Re: Actinium Pharmaceuticals, Inc. Registration Statement on Form S-3 Originally filed on August 11, 2023, as amended on February 2, 2024 File No. 333-27 |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| November 2, 2023 |
Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”) is made and entered into as of this first day of November, 2023 (the “Amendment Effective Date”), by and between Actinium Pharmaceuticals, Inc. (the “Company”) and Sandesh Seth (the “Executive”) for purposes of amending that certain employment agreement dated as of August 12, 2020, by and betwe |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTIN |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM P |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Actinium Pharmaceuticals, Inc. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Under Section 13 or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition Report Under Section 13 or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 000-52446 ACTINIUM PHARMACEUTICALS, |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| February 21, 2023 |
Exhibit 99.2 ATNM: NYSE AMERICAN February 18, 2022 Iomab - B SIERRA Trial Phase 3 Results Disclaimer and Safe Harbor The information presented herein contains express and implied forward - looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Actinium Pharmaceuticals, Inc . (“Actinium”) that are not historical facts . These forward - looking statemen |
|
| February 21, 2023 |
Exhibit 99.1 Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia - Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B a |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2023 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| February 6, 2023 |
ATNM / Actinium Pharmaceuticals Inc / BIGGER CAPITAL FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W206 (CUSIP N |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| December 30, 2022 |
Exhibit 10.1 Fourth AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. 2019 Stock PLAN This Fourth Amendment to Actinium Pharmaceuticals, Inc. 2019 Stock Plan (this “Amendment”), effective as of December 30, 2022, is made and entered into by Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined here |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTIN |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| October 31, 2022 |
Exhibit 99.1 Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia - Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of <0.0001 NEW YORK, NY – October 31, 2022 – Actinium Pharmaceuticals, Inc. (NYSE AMERIC |
|
| August 19, 2022 |
Exhibit 99.4 THIRD AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. 2019 Stock PLAN This THIRD Amendment to Actinium Pharmaceuticals, Inc. 2019 Stock Plan (this ?Amendment?), effective as of August 10, 2022, is made and entered into by Actinium Pharmaceuticals, Inc., a Delaware corporation (the ?Company?). Terms used in this Amendment with initial capital letters that are not otherwise defined herein s |
|
| August 19, 2022 |
EX-FILING FEES 5 ea156670ex-feeactiniumpha.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Actinium Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offer |
|
| August 19, 2022 |
As filed with the Securities and Exchange Commission on August 19, 2022 As filed with the Securities and Exchange Commission on August 19, 2022 Registration No. |
|
| August 12, 2022 |
Exhibit 10.2 EXECUTION COPY AGREEMENT OF SUBLEASE between ABN AMRO HOLDING USA LLC as Sublandlord and ACTINIUM PHARMACEUTICALS, INC. as Subtenant Premises: Entire 23rd Floor 100 Park Avenue New York, New York 10017 AGREEMENT OF SUBLEASE THIS AGREEMENT OF SUBLEASE (this ?Sublease?), made and entered into as of the day of April, 2022, by and between ABN AMRO HOLDING USA LLC, a Delaware limited liabi |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM P |
|
| August 12, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION MARKED BY [*] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AND SUPPLY AGREEMENT THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (?Agreement?) is made effective as of the 7th day of April, 2022 (the ?Effective Date?), by an |
|
| June 29, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| June 29, 2022 |
Exhibit 1.1 ACTINIUM PHARMACEUTICALS, INC. Common Stock ($0.001 par value per share) Amended and Restated Capital on Demand™ Sales Agreement June 28, 2022 JonesTrading Institutional Services LLC 211 East 43rd Street, 15th Floor New York, NY 10017 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Actinium Pharmaceuticals, Inc., a Delaware corporation (th |
|
| June 28, 2022 |
Actinium Pharmaceuticals, Inc. Up to $200,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-242322 Amendment No. 1 Dated June 28, 2022 (to Prospectus dated August 14, 2020) Actinium Pharmaceuticals, Inc. Up to $200,000,000 Common Stock This Amendment No. 1 to Prospectus, or this amendment, amends our sales agreement prospectus dated August 14, 2020, or the sales agreement prospectus and together with this amendment, the prospectus. Th |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| April 13, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2021 or ? Transition Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 000-52446 ACTINIUM PHARMACEUTICALS, |
|
| February 9, 2022 |
ATNM / Actinium Pharmaceuticals Inc / BIGGER CAPITAL FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W206 (CUSIP N |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTI |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| November 9, 2021 |
EXHIBIT 10.1 Second AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. 2019 PLAN This Second Amendment to Actinium Pharmaceuticals, Inc. 2019 Plan (this ?Amendment?), effective as of November 9, 2021, is made and entered into by Actinium Pharmaceuticals, Inc., a Delaware corporation (the ?Company?). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| September 23, 2021 |
Exhibit 99.1 Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel - Arun Swaminathan, Ph.D. appointed as Chief Business and Commercial Officer, bringing 20+ years of industry experience in large pharmaceutical and biotech organizations - Avinash Desai, M.D. promoted to Chie |
|
| September 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) ( |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| March 31, 2021 |
EXHIBIT 4.15 DESCRIPTION OF SECURITIES The foregoing description is intended as a summary and is qualified in its entirety by reference to our certificate of incorporation, as amended (the ?Certificate of Incorporation?) and our amended and restated by-laws, as amended (the ?By-laws?) as currently in effect, copies of which are filed as exhibits to this Annual Report on Form 10-K and are incorpora |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2020 or ? Transition Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 000-52446 ACTINIUM PHARMACEUTICALS, |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W206 (CUSIP N |
|
| November 20, 2020 |
EXHIBIT 10.1 ACTINIUM PHARMACEUTICALS, INC. 2019 Stock Plan 1. Purposes of the Plan. The purposes of this 2019 Stock Plan of the Company (the “Plan”) are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business. To achieve these purpose |
|
| November 20, 2020 |
Exhibit 10.2 AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. 2019 PLAN This AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. 2019 PLAN (this “Amendment”), effective as of November 18, 2020, is made and entered into by Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings |
|
| November 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| October 28, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| October 28, 2020 |
Upcoming Data Could Set Stage for Expanded Market Opportunity in R/R AML Exhibit 99.1 October 2020 Dear Actinium Shareholder: In 2020 thus far, we have made steady progress with our Iomab-B SIERRA pivotal trial, which is in its final quartile of enrollment, and our Actimab-A combination trials in the Relapsed and Refractory Acute Myeloid Leukemia (R/R AML) setting. We are on track and look forward to data updates related to this progress by year-end; specifically, data |
|
| October 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| October 23, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTI |
|
| October 7, 2020 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| October 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| August 14, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| August 14, 2020 |
Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split Exhibit 99.1 Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split NEW YORK, NY – August 10, 2020 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that its Board of Directors approved a 1-for-30 reverse split of its issued and outstanding common stock that will become effective after trading closes on August 10, 2020. Trading of the Compan |
|
| August 14, 2020 |
Exhibit 10.5 August 12, 2020 Dr. Dale Ludwig 275 Madison Avenue, Suite 702 New York, NY 10016 Dear Dr. Ludwig, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract (the “Agreement”) related to your position as Chief Scientific and Technology Officer of the Company. This Agreement replaces and supersedes the employment agreement between you and |
|
| August 14, 2020 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ACTINIUM PHARMACEUTICALS, INC. Actinium Pharmaceuticals, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. The name of the corporation is Actinium Pharmaceuticals, Inc. 2. Effective as of 5:00 p.m., Eastern Time, on Augus |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2020 |
Exhibit 10.6 August 12, 2020 Mark S. Berger, M.D. 275 Madison Avenue, Suite 702 New York, NY 10016 Dear Dr. Berger, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract (the “Agreement”) related to your position as Chief Medical Officer of the Company. This Agreement replaces and supersedes the employment agreement between you and the Company |
|
| August 14, 2020 |
Exhibit 10.3 August 12, 2020 Sandesh Seth 275 Madison Avenue, Suite 702 New York, NY 10016 Dear Mr. Seth: On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract (the “Agreement”) related to your position as Chief Executive Officer and Chairman of the Board of the Company. This Agreement replaces your employment agreement with the Company dated A |
|
| August 14, 2020 |
CORRESP 1 filename1.htm Actinium Pharmaceuticals, Inc. 275 Madison Avenue, 7th Floor New York, New York 10016 August 14, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 Attention: Laura Crotty Re: Actinium Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 7, 2020 File No. 333-242322 |
|
| August 14, 2020 |
Exhibit 10.4 August 12, 2020 Steve O’Loughlin 275 Madison Avenue, Suite 702 New York, NY 10016 Dear Mr. O’Loughlin, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract (the “Agreement”) related to your position as Chief Financial Officer of the Company. This Agreement replaces and supersedes the employment agreement between you and the Compan |
|
| August 14, 2020 |
Exhibit 10.2 Amendment to Warrant to purchase common stock of Actinium pharmaceuticals, Inc. This amendment to Warrant to purchase common stock oF Actinium pharmaceuticals, Inc. (this “Amendment”) is effective as of August 12, 2020 (the “Effective Date”), and is entered into by and between Sandesh Seth (the “Holder”) and Actinium Pharmaceuticals, Inc. (the “Company”). Capitalized terms not otherwi |
|
| August 12, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated August 11, 2020 with respect to the shares of Common Stock of Actinium Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) |
|
| August 12, 2020 |
ATNM / Actinium Pharmaceuticals, Inc. / BIGGER CAPITAL FUND L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W206 (CUSIP Nu |
|
| August 7, 2020 |
Exhibit 1.2 ACTINIUM PHARMACEUTICALS, INC. Common Stock ($0.001 par value per share) Capital on Demand™ Sales Agreement August 7, 2020 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 Ladies and Gentlemen: Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services |
|
| August 7, 2020 |
As filed with the Securities and Exchange Commission on August 7, 2020 Registration No. |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Com |
|
| July 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| July 13, 2020 |
Annual Report - AMENDMENT NO. 2 TO FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ Annual Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 001-36374 ACTINI |
|
| June 30, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36374 ACTINIUM |
|
| June 19, 2020 |
Actinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering Exhibit 99.1 Actinium Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering NEW YORK, NY – June 19, 2020 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the closing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.3 |
|
| June 19, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| June 18, 2020 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| June 18, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 Prospectus Supplement (To Prospectus Dated October 12, 2017) 55,653,846 Shares Common Stock Pre-Funded Warrants to Purchase up to 21,269,231 Shares of Common Stock We are offering 55,653,846 shares of our common stock, par value $0.001 per share. We are also offering pre-funded warrants to purchase up to an aggregate of 21,269,231 shares |
|
| June 18, 2020 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACTINIUM PHARMACEUTICALS, INC. Warrant Shares: Issue Date:, 2020 Initial Exercise Date: , 2020 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| June 18, 2020 |
Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering Exhibit 99.2 Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering NEW YORK, NY – June 16, 2020 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.3 |
|
| June 18, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 16, 2020, between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| June 18, 2020 |
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering Exhibit 99.1 Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering NEW YORK, NY – June 16, 2020 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) in a public offering. The offering is subject to market and other conditions, and th |
|
| June 16, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are not soliciting an |
|
| June 16, 2020 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ACTINIUM PHARMACEUTICALS, INC. Actinium Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: 1. The Certificate of Incorporation is amended (a) by replacing Article FOURTH thereof to read in its entirety |
|
| June 16, 2020 |
EXHIBIT 4.14 DESCRIPTION OF SECURITIES The foregoing description is intended as a summary and is qualified in its entirety by reference to our certificate of incorporation, as amended (the “Certificate of Incorporation”) and our amended and restated by-laws, as amended (the “By-laws”) as currently in effect, copies of which are filed as exhibits to this Amendment No. 1 to the Annual Report on Form |
|
| June 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| June 16, 2020 |
Annual Report - AMENDMENT NO.1 TO FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ Annual Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 001-36374 ACTINI |
|
| June 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36374 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commis |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 000-52446 ACTINIUM PHARMACEUTICALS, |
|
| May 5, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commiss |
|
| May 5, 2020 |
Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS APPROVED BY THE BOARD OF DIRECTORS OF ACTINIUM PHARMACEUTICALS, INC. EFFECTIVE AS OF MAY 5, 2020 Article XI of the Amended and Restated Bylaws (the “Bylaws”) of Actinium Pharmaceuticals, Inc. (the “Corporation”) is hereby added to the Bylaws, and the following Article XI be, and hereby is, is authorized, approved and adopted in all respects |
|
| April 27, 2020 |
ATNM / Actinium Pharmaceuticals, Inc. / Bigger Capital Fund L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W107 (CUSIP N |
|
| April 24, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| April 24, 2020 |
Exhibit 1.1 Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Pre-Funded Warrants to Purchase Common Stock Underwriting Agreement April 21, 2020 H.C. Wainwright & Co., LLC As Representative of the several Underwriters named in Schedule I attached hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Actinium Pharmaceuticals, Inc., a Delaware corporation ( |
|
| April 24, 2020 |
Exhibit 4.1 Form of Warrant PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACTINIUM PHARMACEUTICALS, INC. Warrant Shares: Issue Date:, 2020 Initial Exercise Date: , 2020 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fo |
|
| April 22, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 Prospectus Supplement (To Prospectus Dated October 12, 2017) 100,833,333 Shares Common Stock Pre-Funded Warrants to Purchase up to 82,500,001 Shares of Common Stock We are offering 100,833,333 shares of our common stock, par value $0.001 per share. Each share of common stock is being sold at a public offering price of $0.15 per share. We |
|
| April 21, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are not soliciting an |
|
| March 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2020 |
ATNM / Actinium Pharmaceuticals, Inc. / Bigger Capital Fund L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W107 (CUSIP N |
|
| December 19, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2019 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| December 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2019 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| November 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def |
|
| November 25, 2019 |
8-K 1 f8k112519actiniumpharm.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2019 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 ( |
|
| November 15, 2019 |
ATNM / Actinium Pharmaceuticals, Inc. PRE 14A - - PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTI |
|
| October 31, 2019 |
ATNM / Actinium Pharmaceuticals, Inc. / Bigger Capital Fund L P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W107 (CUSIP Nu |
|
| October 31, 2019 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 28, 2019 with respect to the shares of Common Stock of Actinium Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1 |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTINIUM |
|
| June 7, 2019 |
8-K 1 f8k060719actiniumpharm.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State |
|
| May 10, 2019 |
ATNM / Actinium Pharmaceuticals, Inc. S-8 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on May 10, 2019 Registration No. |
|
| May 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTINIUM |
|
| April 18, 2019 |
Exhibit 1.1 Execution Version Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Warrants to Purchase Common Stock Underwriting Agreement April 18, 2019 William Blair & Company, L.L.C. As representative of the several Underwriters named in Schedule I hereto, c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Actiniu |
|
| April 18, 2019 |
Form of Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on April 18, 2019). Exhibit 4.1 Form of Warrant COMMON STOCK PURCHASE WARRANT ACTINIUM PHARMACEUTICALS, INC. Warrant Shares: [ ] Warrant Number: [ ] Issue Date: April 23, 2019 Actinium Pharmaceuticals, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered h |
|
| April 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2019 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| April 18, 2019 |
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants Exhibit 99.1 Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants NEW YORK, NY – April 17, 2019 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase additional shares of its common stock in an underwr |
|
| April 18, 2019 |
Exhibit 99.2 Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants NEW YORK, NY – April 18, 2019 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced the pricing of an underwritten public offering of 42,860,000 shares of its common stock at a combined public offering price of $0.385 per share of common stock. T |
|
| April 18, 2019 |
42,860,000 Shares Common Stock Warrants to Purchase 42,860,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 Prospectus Supplement (To Prospectus Dated October 24, 2017) 42,860,000 Shares Common Stock Warrants to Purchase 42,860,000 Shares Common Stock We are offering 42,860,000 shares of our common stock and warrants to purchase up to 42,860,000 shares of our common stock. Each share of our common stock is being sold together with a warrant to |
|
| April 17, 2019 |
SUBJECT TO COMPLETION, DATED April 17, 2019 The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Filed Pursuant to Rule 42 |
|
| March 15, 2019 |
Exhibit 10.37 CONSULTING AGREEMENT Effective Date: December 22, 2019 THIS CONSULTING AGREEMENT (this “Agreement”) is entered into by and between Actinium Pharmaceuticals, Inc., a Delaware corporation with a business address at Actinium Pharmaceuticals, Inc., having a place of business at 275 Madison Ave, 7th Floor, New York, NY. 10016, (“API”). (the “Company”), and Nitya G. Ray, Ph.D. with a busin |
|
| March 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2018 or ☐ Transition Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 000-52446 ACTINIUM PHARMACEUTICALS, |
|
| March 15, 2019 |
Exhibit 3.7 |
|
| March 15, 2019 |
Exhibit 10.38 ACTINIUM PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) Amended and Restated At Market Issuance Sales Agreement December 28, 2018 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY 10017 JonesTrading Institutional Services LLC 757 Third Avenue, 23rd Floor New York, NY 10017 Ladies and Gentlemen: Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Com |
|
| March 15, 2019 |
Exhibit 10.39 AMENDMENT NO. 7 TO ACTINIUM PHARMACEUTICALS, INC. 2013 AMENDED AND RESTATED STOCK PLAN Pursuant to Section 14 of the 2013 Amended and Restated Stock Plan, as amended (the “Plan”) of Actinium Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company has duly adopted a resolution, conditioned upon approval by the stockholders of the Company, approving this Amendment |
|
| March 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2019 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2019 |
ATNM / Actinium Pharmaceuticals, Inc. / Frigate Ventures LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No. |
|
| December 28, 2018 |
Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-216748 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 24, 2017) $75,000,000 Common Stock In accordance with the terms of the Amended and Restated At Market Issuance Sales Agreement entered into with B. Riley FBR, Inc., or B. Riley FBR and JonesTrading Institutional Services LLC, or JonesTrading (collectively, B. Riley FBR and Jone |
|
| December 28, 2018 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| December 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| December 21, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| November 16, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def |
|
| November 9, 2018 |
Exhibit 4.3 AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Pursuant to Section 9(a) of the Warrant to Purchase Common Stock of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), originally dated December 17, 2012, issued to Bioche Asset Management, LCC in the amount of 721,068 warrant shares, the Board of Directors of the Company has duly adopted a res |
|
| November 9, 2018 |
Exhibit 4.1 AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Pursuant to Section 9(a) of the Warrant to Purchase Common Stock of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), originally dated December 17, 2012, issued to Amrosan LLC in the amount of 375,556 warrant shares, the Board of Directors of the Company has duly adopted a resolution approving |
|
| November 9, 2018 |
Exhibit 4.2 AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK Pursuant to Section 9(a) of the Warrant to Purchase Common Stock of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), originally dated December 17, 2012, issued to Carnegie Hill Partners in the amount of 353,023 warrant shares, the Board of Directors of the Company has duly adopted a resolutio |
|
| November 9, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTI |
|
| October 30, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. PRELIMINARY PROXY STATEMENT PRE 14A 1 pre14a1018actiniumpharma.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for |
|
| October 18, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| October 18, 2018 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 18, 2018, is entered into by and between ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used |
|
| October 18, 2018 |
Exhibit 10.1 Execution Version PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of October 18, 2018 (the “Execution Date”), is entered into by and between ACTINIUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined her |
|
| October 18, 2018 |
Up to $32,500,000 of Common Stock and 4,229,091 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 Prospectus Supplement (To Prospectus Dated October 24, 2017) Up to $32,500,000 of Common Stock and 4,229,091 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $32,500,000 of shares of our common stock that we may issue to Lincoln Park Capital Fund, LLC (“Lincoln Park”) from time to time under a P |
|
| August 15, 2018 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| August 9, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTINIUM |
|
| August 9, 2018 |
Exhibit 3.1 ACTINIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS (Adopted on August 8, 2018) ARTICLE I—OFFICES Section 1.1 Registered Office The address of the registered office of Actinium Pharmaceuticals, Inc. (hereinafter called the “Corporation”) in the State of Delaware shall be located at the address thereof set forth in the certificate of incorporation of the Corporation (as the same |
|
| August 9, 2018 |
Letter of GBH CPAs, PC to the Securities and Exchange Commission dated August 9, 2018. Exhibit 16.1 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Ladies and Gentleman: We have read the statements under Item 4.01 included in Item 5 - Other Information in the Form 10-Q of Actinium Pharmaceuticals, Inc. (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein |
|
| August 9, 2018 |
Exhibit 10.2 August 8, 2018 Steve O’Loughlin 317 21st Street Union City, NJ 07087 Dear Mr. O’Loughlin, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract related to your position as Principal Financial Officer of the Company. This agreement (the “Agreement”) amends and restates your September 17, 2015 Employment Agreement (“Prior Agreement”) |
|
| August 9, 2018 |
Exhibit 10.1 August 8, 2018 Sandesh Seth 244 Fifth Avenue, 2nd Floor Suite S217 New York, NY 10001 Dear Mr. : On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to provide you with this contract (the “Agreement”) related to your position as Chief Executive Officer and Chairman of the Board of the Company. This Agreement replaces your August 6, 2015 Executive Chairman Agreeme |
|
| May 10, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTINIUM |
|
| May 1, 2018 |
Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into and effective on the date set forth below, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Jeffrey W. Chell (“Indemnitee”). RECITALS WHEREAS, the Corporation, which is organized under the General Corporation Law of the State of Delaware (a |
|
| May 1, 2018 |
8-K 1 f8k042718actiniumpharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (St |
|
| May 1, 2018 |
Exhibit 10.1 April 27, 2018 Jeffrey W. Chell, M.D. 521 Mandalay Avenue #708 Clearwater Beach, FL 33767 Dear Dr. Chell: On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of a director of the Company’s Board of Directors (the “Board”). Speaking for myself, as well as the other members of the Company’s Board, we are all very impressed with your creden |
|
| May 1, 2018 |
Exhibit 10.3 Actinium Pharmaceuticals, Inc. CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT THIS CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT (this “Agreement”) is made and entered into and effective on the date set forth below, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation, or any of its current or future subsidiaries, affiliates, successors or a |
|
| March 16, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March 16, 2018 Registration No. |
|
| March 16, 2018 |
Exhibit 10.59 January 31, 2018 Mr. Anil Kapur 7 Wellington Drive Basking Ridge, NJ 07926 Dear Mr. Kapur, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Chief Commercial Officer. Speaking for myself, as well as the other members of the Company’s Board of Directors (the “Board”), we are all very impressed with your credentials and look forward |
|
| March 16, 2018 |
Exhibit 10.56 AMENDMENT NO. 6 TO ACTINIUM PHARMACEUTICALS, INC. 2013 AMENDED AND RESTATED STOCK PLAN Pursuant to Section 14 of the 2013 Amended and Restated Stock Plan, as amended (the “Plan”) of Actinium Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company has duly adopted a resolution, conditioned upon approval by the stockholders of the Company, approving this Amendment |
|
| March 16, 2018 |
Exhibit 10.60 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this 8th day of February, 2018, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Anil Kapur (“Indemnitee”). RECITALS WHEREAS, the Corporation, which is organized under the General Corporation Law of the State of Delaware (as amended, the “ |
|
| March 16, 2018 |
Exhibit 10.57 October 16, 2017 Dale Ludwig 21 Fernwood Road Rockaway, NJ 07866-2028 Dear Mr. Ludwig, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Chief Scientific Officer. This position serves as a named executive officer of the company. Speaking for myself, as well as the other members of the Company’s Board of Directors (the “Board”), we |
|
| March 16, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the fiscal year ended December 31, 2017 or ☐ Transition Report Under Section 13 Or 15(d) Of The Securities Exchange Act Of 1934 For the transition period from to COMMISSION FILE NUMBER: 000-52446 ACTINIUM PHARMACEUTICALS, |
|
| March 16, 2018 |
Exhibit 10.58 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this 5th day of January, 2018, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Dale L. Ludwig (“Indemnitee”). RECITALS WHEREAS, the Corporation, which is organized under the General Corporation Law of the State of Delaware (as amended, th |
|
| March 13, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. / Frigate Ventures LP - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Actinium Pharmaceuticals, Inc. |
|
| March 13, 2018 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common stock, par value $.001 per share, of Actinium Pharmaceuticals, Inc. a Delaware corporation, and fur |
|
| March 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| February 26, 2018 |
Subscription Rights to Purchase Up to 50,000,000 Units 424B5 1 f424b5022318actinium.htm PROSPECTUS SUPPLEMENT NO. 1 Amendment No. 1 Dated February 26, 2017 to Prospectus Supplement Dated February 15, 2017 (To Prospectus Dated October 24, 2017) Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 Subscription Rights to Purchase Up to 50,000,000 Units This amendment amends and supplements the prospectus supplement dated February 15, 2018, which |
|
| February 26, 2018 |
Exhibit 4.1 FORM OF NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE RIGHTS CERTIFICATE # [] NUMBER OF RIGHTS: [] THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS SUPPLEMENT DATED FEBRUARY 15, 2018, AS AMENDED FEBRUARY 26, 2018, AS IT MAY BE FURTHER AMENDED FROM TIME TO TIME (THE ?PROSPECTUS SUPPLEMENT?), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF |
|
| February 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| February 26, 2018 |
Exhibit 99.1 Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and Amendment to Pricing Terms of its Rights Offering - Pricing of the units has been amended to $0.50 per unit with corresponding amendments to the warrant exercise prices - Timing of the offering is expected to be unchanged and the subscription period is expected to end on March 2 |
|
| February 26, 2018 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Actinium Pharmaceuticals, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incor |
|
| February 26, 2018 |
FORM OF BENEFICIAL OWNER ELECTION FORM ACTINIUM PHARMACEUTICALS, INC. Exhibit 99.2 FORM OF BENEFICIAL OWNER ELECTION FORM ACTINIUM PHARMACEUTICALS, INC. The undersigned acknowledge(s) receipt of your letter and the enclosed materials referred to therein relating to the rights offering (the ?Rights Offering?) by Actinium Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), of non-transferable subscription rights (the ?Subscription Rights?) to purchase units |
|
| February 15, 2018 |
Subscription Rights to Purchase Up to 35,714,285 Units Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 Prospectus Supplement (To Prospectus Dated October 24, 2017) Subscription Rights to Purchase Up to 35,714,285 Units We are distributing to holders of our common stock and to holders of certain of our outstanding warrants who are entitled to participate in this offering, at no charge, non-transferable subscription rights to purchase up to |
|
| February 15, 2018 |
FORM OF BENEFICIAL OWNER ELECTION FORM ACTINIUM PHARMACEUTICALS, INC. Exhibit 99.5 FORM OF BENEFICIAL OWNER ELECTION FORM ACTINIUM PHARMACEUTICALS, INC. The undersigned acknowledge(s) receipt of your letter and the enclosed materials referred to therein relating to the rights offering (the ?Rights Offering?) by Actinium Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), of non-transferable subscription rights (the ?Subscription Rights?) to purchase units |
|
| February 15, 2018 |
Exhibit 4.1 Actinium Pharmaceuticals, Inc. and Action Stock Transfer Corporation, as Warrant Agent Warrant Agency Agreement Dated as of [ ] WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of [ ] (?Agreement?), between Actinium Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Action Stock Transfer Corporation (the ?Warrant Agent?). WITNESSETH WHEREAS, pursuant to a reg |
|
| February 15, 2018 |
Exhibit 99.1 FORM OF INSTRUCTIONS AS TO USE OF SUBSCRIPTION RIGHTS CERTIFICATES ACTINIUM PHARMACEUTICALS, INC. Please consult Broadridge Corporate Issuer Solutions, Inc., as to any questions. The following instructions relate to a rights offering (the ?Rights Offering?) by Actinium Pharmaceuticals, Inc., a Delaware corporation (?Actinium?), to the holders of record of its common stock, $0.001 par |
|
| February 15, 2018 |
FORM OF NOTICE OF IMPORTANT TAX INFORMATION ACTINIUM PHARMACEUTICALS, INC. Exhibit 99.7 FORM OF NOTICE OF IMPORTANT TAX INFORMATION ACTINIUM PHARMACEUTICALS, INC. The tax information is provided in connection with the prospectus of Actinium Pharmaceuticals, Inc. (?Actinium?) dated February 15, 2018 (the ?Prospectus Supplement?). Under the U.S. federal income tax laws, dividend payments (including constructive dividends) that may be made by Actinium on shares of its Commo |
|
| February 15, 2018 |
Exhibit 99.4 FORM OF BROKER LETTER TO CLIENTS WHO ARE BENEFICIAL HOLDERS ACTINIUM PHARMACEUTICALS, INC. Subscription Rights to Purchase Units Offered Pursuant to Subscription Rights Distributed to Shareholders of Actinium Pharmaceuticals, Inc. February 15, 2018 To our Clients: This letter is being distributed to our clients who are holders of Actinium Pharmaceuticals, Inc. (the ?Company?) common s |
|
| February 15, 2018 |
Exhibit 99.2 FORM OF LETTER TO STOCKHOLDERS AND PARTICIPATING WARRANT HOLDERS WHO ARE RECORD HOLDERS ACTINIUM PHARMACEUTICALS, INC. Subscription Rights to Purchase Units Offered Pursuant to Subscription Rights Distributed to Stockholders and Participating Warrant Holders of Actinium Pharmaceuticals, Inc. February 15, 2018 Dear Stockholder and Participating Warrant Holder: This letter is being dist |
|
| February 15, 2018 |
Exhibit 1.1 ACTINIUM PHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENT February 15, 2018 Maxim Group LLC 405 Lexington Avenue New York, NY 10174 As Dealer-Manager Ladies and Gentlemen: The following (this ?Agreement?) will confirm our agreement relating to the proposed rights offering (the ?Rights Offering?) to be undertaken by Actinium Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), p |
|
| February 15, 2018 |
FORM OF NOMINEE HOLDER CERTIFICATION ACTINIUM PHARMACEUTICALS, INC. Exhibit 99.6 FORM OF NOMINEE HOLDER CERTIFICATION ACTINIUM PHARMACEUTICALS, INC. The undersigned, a bank, broker, dealer, trustee, depositary, or other nominee of non-transferable subscription rights (the "Subscription Rights") to purchase units ("Units") of Actinium Pharmaceuticals, Inc. (the "Company"), said Units each comprised of one share of Common Stock, 0.25 Series A Warrants, and 0.75 Seri |
|
| February 15, 2018 |
Exhibit 4.3 SERIES B COMMON STOCK PURCHASE WARRANT ACTINIUM PHARMACEUTICALS, INC. Warrant Shares: [ ] Initial Exercise Date: March [ ], 2018 Warrant Number: [ ] Issue Date: March [ ], 2018 CUSIP: [ ] ISIN: [ ] THIS SERIES B COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Cede & Co. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limita |
|
| February 15, 2018 |
Exhibit 4.2 SERIES A COMMON STOCK PURCHASE WARRANT ACTINIUM PHARMACEUTICALS, INC. Warrant Shares: [ ] Initial Exercise Date: March [ ], 2018 Warrant Number: [ ] Issue Date: March [ ], 2018 CUSIP: [ ] ISIN: [ ] THIS SERIES A COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Cede & Co. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limita |
|
| February 15, 2018 |
Exhibit 4.4 FORM OF NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE RIGHTS CERTIFICATE # [] NUMBER OF RIGHTS: [] THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS SUPPLEMENT DATED February 15, 2018 (AS IT MAY BE AMENDED FROM TIME TO TIME, THE ?PROSPECTUS SUPPLEMENT?) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS SUPPLEMENT ARE AVAILABLE |
|
| February 15, 2018 |
Exhibit 99.3 FORM OF LETTER TO BROKERS, DEALERS, BANKS AND OTHER NOMINEES ACTINIUM PHARMACEUTICALS, INC. Subscription Rights to Purchase Units Offered Pursuant to Subscription Rights Distributed to Shareholders and Participating Warrant Holders of Actinium Pharmaceuticals, Inc. February 15, 2018 To Brokers, Dealers, Banks and Other Nominees: This letter is being distributed by Actinium Pharmaceuti |
|
| February 15, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| February 14, 2018 |
ATNM / Actinium Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Actinium Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00507W107 (CUSIP N |
|
| February 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| February 1, 2018 |
Subject to Completion, dated February 1, 2017 Filed Pursuant to Rule 424(b)(5) Registration No. 333-216748 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| January 25, 2018 |
Key December Events and Their Relevance Company Fact Sheet Investor Contacts: Exhibit 99.2 Addendum Key December Events and Their Relevance & Company Fact Sheet Investor Contacts: Steve O?Loughlin Marek Ciszewski, J.D. Principal Financial Officer. Managing Director, Head of Life Sciences Actinium Pharmaceuticals, Inc. Liolios Investor Relations [email protected] [email protected] Actinium Pharmaceuticals, Inc. 275 Madison Avenue, Suite 702 New York, New York 1001 |
|
| January 25, 2018 |
Letter to Investors Company Update and Outlook for 2018 Exhibit 99.1 Letter to Investors Company Update and Outlook for 2018 On behalf of the team at Actinium, I would like to wish you all an awesome 2018 and also thank our many shareholders for their unstinting support of the Company’s proposals for the Annual Shareholder Meeting in December, all of which passed with resounding majorities. After bearing witness to the Company’s performance over the pa |
|
| January 25, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Co |
|
| January 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2018 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Com |
|
| December 21, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2017 |
ATNM / Actinium Pharmaceuticals, Inc. DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Def |
|
| November 3, 2017 |
ATNM / Actinium Pharmaceuticals, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTI |
|
| October 30, 2017 |
Actinium Pharmaceuticals PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def |
|
| October 24, 2017 |
ACTINIUM PHARMACEUTICALS, INC. Common Stock Preferred Stock Debt Securities Purchase Contracts Filed Pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No. |
|
| October 24, 2017 |
ACTINIUM PHARMACEUTICALS, INC. Common Stock Filed Pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No. |
|
| October 10, 2017 |
ATNM / Actinium Pharmaceuticals, Inc. ESP ACTINIUM PHARMACEUTICALS, INC. 275 Madison Avenue, 7th Floor New York, New York 10016 October 10, 2017 VIA EDGAR Ms. Mary Beth Breslin Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 RE: Actinium Pharmaceuticals, Inc. (the "Company") Registration Statement on Form S-3 (File No. 333-216748) (the "Registration Statement") Dear Ms. Breslin: The Company hereby requests, pursua |
|
| October 3, 2017 |
Actinium Pharmaceuticals AMENDMENT NO. 1 TO FORM S-3 As filed with the Securities and Exchange Commission on October 3, 2017 Registration No. |
|
| October 3, 2017 |
ATNM / Actinium Pharmaceuticals, Inc. ESP CORRESP 1 filename1.htm Actinium Pharmaceuticals, Inc. 275 Madison Avenue, 7th Floor New York, NY 10016 October 3, 2017 VIA EDGAR Irene Paik Dorrie Yale Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Actinium Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2016 Filed March 16, 2 |
|
| October 3, 2017 |
ATNM / Actinium Pharmaceuticals, Inc. ESP Actinium Pharmaceuticals, Inc. 275 Madison Avenue, 7th Floor New York, NY 10016 October 3, 2017 VIA EDGAR Johnny Gharib Mary Beth Breslin Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Actinium Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 16, 2017 File No. 333-216748 Dear Mr.Gharib and Ms. Breslin: We are in r |
|
| August 4, 2017 |
Exhibit 10.8 SEPARATION AND SETTLEMENT AGREEMENT BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND DR. KAUSHIK J. DAVE This Separation and Settlement Agreement (“Agreement”), dated as of May 12, 2017 (the “Effective Date”), is made by and between Actinium Pharmaceuticals, Inc., a Delaware company (“Actinium” or the “Company”), and Dr. Kaushik J. Dave (“Employee”). WHEREAS, Employee was employed by |
|
| August 4, 2017 |
Exhibit 10.1 THIS ASSIGNMENT AND CONSENT AGREEMENT (this “Agreement”), made as of the 6th day of June, 2017, between 275 MADISON AVENUE RPW 1 LLC and 275 MADISON AVENUE RPW 2 LLC, having an office in care of RPW Group, Inc., 800 Westchester Avenue, Rye Brook, New York 10573, hereinafter referred to collectively as the “Owner,” RELMADA THREAPEUTICS, INC., having an office at 275 Madison Avenue, Sui |
|
| August 4, 2017 |
Exhibit 10.9 SEPARATION AND SETTLEMENT AGREEMENT BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND DRAGAN CICIC This Separation and Settlement Agreement (“Agreement”), dated as of May 12, 2017 (the “Effective Date”), is made by and between Actinium Pharmaceuticals, Inc., a Delaware company (“Actinium” or the “Company”), and Dragan Cicic (“Employee”). WHEREAS, Employee was employed by the Company p |
|
| August 4, 2017 |
ATNM / Actinium Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 4, 2017 |
Exhibit 10.3 AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is entered on this 8th day of June, 2017, between Relmada Therapeutics, Inc., a Nevada corporation (“Relmada”), and Actinium Pharmaceuticals, Inc., a Delaware corporation (“Actinium”), with respect to the office space (the “Premises”) located on the 7th floor of the office building lo |
|
| August 4, 2017 |
Exhibit 10.6 AGREEMENT This Agreement ("Agreement") is entered into by and between Sergio Traversa ("Director" or "you") and Actinium Pharmaceuticals, Inc. (the "Company" or “Actinium”), and confirms the agreement that has been reached with you in connection with your resignation as a director of the Company (together, the “Parties”). 1. Director Resignation. Based on discussions with the board of |
|
| August 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTINIUM |
|
| August 4, 2017 |
Exhibit 10.4 May 26, 2017 Dr. Nitya G. Ray 14 Baybury Court East Hanover, NJ 07936 Dear Dr. Ray, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain. Speaking for myself, as well as the other members of the Company’s Board of Directors (the “Board”), we are all v |
|
| August 4, 2017 |
Exhibit 10.7 Actinium Pharmaceuticals, Inc. Confidential CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into on May 22, 2017 (the “Effective Date”) by and between Actinium Pharmaceuticals, Inc., a Delaware corporation with a business address at 275 Madison Avenue, 7th Floor, New York, NY 10016 (the “Company”), and Dragan Cicic (“Consultant”). WHEREAS, the Company desires t |
|
| August 4, 2017 |
Exhibit 10.5 ACTINIUM PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) Amended and Restated At-the-Market Market Issuance Sales Agreement July 3, 2017 FBR Capital Markets & Co. 1300 North 17th Street Suite 1400 Arlington, Virginia 22209 MLV & Co. LLC 299 Park Avenue, 7th Floor New York, NY 10171 JonesTrading Institutional Services LLC 780 Third Avenue New York, NY 10017 Ladies and G |
|
| July 31, 2017 |
21,500,000 Shares Common Stock Warrants to Purchase 18,275,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-194768 Prospectus Supplement (To Prospectus Dated April 17, 2014) 21,500,000 Shares Common Stock Warrants to Purchase 18,275,000 Shares of Common Stock We are offering 21,500,000 shares of our common stock and warrants to purchase up to 18,275,000 shares of our common stock. Each share of our common stock is being sold together with a warrant t |
|
| July 28, 2017 |
Actinium Pharmaceuticals CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commi |
|
| July 28, 2017 |
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock Exhibit 99.1 Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock New York, NY ? July 27, 2017 ? Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (?Actinium? or ?the Company?), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that it intends to offer and sell shares of its |
|
| July 28, 2017 |
Form of Warrant (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 28, 2017). Exhibit 10.1 [FORM OF WARRANT] ACTINIUM PHARMACEUTICALS, INC. Warrant To Purchase Common Stock Warrant No.: Number of Shares of Common Stock: Date of Issuance: August [ ], 2017 (?Issuance Date?) Actinium Pharmaceuticals, Inc., a company organized under the laws of Delaware (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby a |
|
| July 28, 2017 |
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock Exhibit 99.2 Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock New York, NY – July 28, 2017 – Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today the pricing of an underwritten public |
|
| July 28, 2017 |
Exhibit 1.1 Actinium Pharmaceuticals, Inc. 21,500,000 Shares of Common Stock and Warrants to Purchase up to 18,275,000 Shares of Common Stock UNDERWRITING AGREEMENT July 28, 2017 Oppenheimer & Co. Inc. As Representative of the Several Underwriters named in Schedule I hereto 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Actinium Pharmaceuticals, Inc., a Delaware corporation (the ?C |
|
| July 27, 2017 |
424B5 1 f424b5022717actiniumphar.htm This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities and |
|
| July 3, 2017 |
Actinium Pharmaceuticals CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commis |
|
| July 3, 2017 |
Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-194768 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 18, 2014) $75,000,000 Common Stock In accordance with the terms of the Amended and Restated At Market Issuance Sales Agreement entered into with FBR Capital Markets & Co., or FBR, JonesTrading Institutional Services LLC, or JonesTrading and MLV & Co. LLC, or MLV (collectively, FB |
|
| June 16, 2017 |
8-K 1 f8k061517actiniumpharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (Sta |
|
| June 9, 2017 |
Actinium Pharmaceuticals CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commis |
|
| June 8, 2017 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commis |
|
| May 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Comm |
|
| May 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2017 ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-52446 74-2963609 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52446 ACTINIUM |
|
| May 15, 2017 |
Exhibit 10.2 September 17, 2015 Steve O’Loughlin 3312 Hudson Avenue Apartment 8E Union City, NJ 07087 Dear Mr. O’Loughlin, On behalf of Actinium Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Senior Director of Finance and Corporate Development. Speaking for myself, as well as the other members of the Company’s Board of Directors (the “Board”), we are all very imp |
|
| May 15, 2017 |
Exhibit 10.3 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this 15th day of May, 2017, by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Steve O’Loughlin (“Indemnitee”). RECITALS WHEREAS, the Corporation, which is organized under the General Corporation Law of the State of Delaware (as amended, the |
